Compare CELH & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELH | RGEN |
|---|---|---|
| Founded | 2004 | 1981 |
| Country | United States | United States |
| Employees | N/A | 2000 |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 10.0B |
| IPO Year | 2008 | 1995 |
| Metric | CELH | RGEN |
|---|---|---|
| Price | $28.35 | $191.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | $64.81 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 6.5M | 829.9K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | ★ 0.47 | 0.24 |
| Revenue | ★ $1,318,014,000.00 | $141,236,000.00 |
| Revenue This Year | $37.04 | $14.30 |
| Revenue Next Year | $9.89 | $14.52 |
| P/E Ratio | ★ $62.09 | $768.88 |
| Revenue Growth | ★ 101.65 | 35.10 |
| 52 Week Low | $23.56 | $100.99 |
| 52 Week High | $66.74 | $188.95 |
| Indicator | CELH | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 63.06 |
| Support Level | $27.23 | $158.15 |
| Resistance Level | $30.20 | $188.73 |
| Average True Range (ATR) | 0.93 | 5.50 |
| MACD | 0.01 | 0.85 |
| Stochastic Oscillator | 54.88 | 81.32 |
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.